Biotechnology News and Research

RSS

Maternal obesity may contribute to cognitive impairment in extremely premature babies

Maternal obesity may contribute to cognitive impairment in extremely premature babies, according to a new study by researchers at Wake Forest Baptist Medical Center.

9 Mar 2012

Genetically modified pig may hold keys to develop treatments for RP

A newly developed, genetically modified pig may hold the keys to the development of improved treatments and possibly even a cure for retinitis pigmentosa (RP), the most common inherited retinal disease in the United States.

9 Mar 2012

Enrollment complete in Palatin's bremelanotide Phase 2B trial for FSD

Palatin Technologies, Inc. today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction.

9 Mar 2012

3SBio, DaVita partner to offer dialysis services in NE China

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) today announced it has entered into an agreement with 3SBio Inc., a leading Chinese biotechnology developer of biopharmaceutical products, to establish a joint venture for providing dialysis treatments in northeastern China.

9 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

FDA approves Teva's ProAir HFA with dose counter for asthma, COPD and EIB

Teva Respiratory announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir HFA with a dose counter for use in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

8 Mar 2012

Scientists believe that ageing can be programmed in the womb

Ageing is a complex process involving physical, psychological, and environmental factors. Scientists believe that ageing can be programmed in the womb. One example of stress during pregnancy is the administration of glucocorticoids, i. e. synthetic stress hormones to accelerate fetal lung maturation in premature labor to allow breathing after birth. Could exposure to these stress hormones have an effect on health later in life?

8 Mar 2012

Dr. Falk Pharma, Lipid Therapeutics enter license agreement for LT-02 to treat UC

Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.

8 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Appendix cancer different from colon cancer

Researchers at Wake Forest Baptist Medical Center have demonstrated that cancer of the appendix is different than colon cancer, a distinction that could lead to more effective treatments for both diseases.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

VBC files patent applications related to beneficial health effects of S-ABA

Valent BioSciences Corporation announced today it has filed worldwide patent applications claiming beneficial health effects of abscisic acid (S-ABA) in humans and animals. S-ABA is a naturally occurring substance found in all plants, including fruits and vegetables.

7 Mar 2012

A&G, Mayo Medical sign license agreement for new progranulin blood test for FTD

Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.

7 Mar 2012

FDA approves Discovery Labs' SURFAXIN to prevent Respiratory Distress Syndrome

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.

6 Mar 2012

EntreMed plans to establish drug development office in China

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has initiated plans to establish an office in China to facilitate the Company's drug development and clinical trials in that country.

6 Mar 2012

Cross Country Healthcare fourth quarter revenue increases 10% to $124.7M

Cross Country Healthcare, Inc. today reported revenue of $124.7 million in the fourth quarter ended December 31, 2011, a 10% increase from revenue of $113.7 million in the prior year quarter and a 5% decrease sequentially from the third quarter of 2011.

6 Mar 2012

PSI 2011 revenue up 25%

PSI, a full-service global CRO known for on-time patient enrollment and project delivery, announces 2011 results reporting record growth in new client wins and 25% year-over-year revenue increase.

6 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

Thrombotech receives FDA IND approval for THR-18 Phase IIa clinical trial in stroke victims

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced Thrombotech Ltd., a portfolio company which Hadasit holds a 24% stake in, received an IND approval from the Food and Drug Administration enabling the initiation of a Phase IIa clinical trial in the U.S.

5 Mar 2012